1
|
Li ST and Chi P: Evolution of the
management of colorectal cancer using integrative medicine. Chin J
Integr Med. 17:73–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Waldner MJ and Neurath MF: The molecular
therapy of colorectal cancer. Mol Aspects Med. 31:171–178. 2010.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Barnes MN and Pustilnik TB: Current
strategies in gene therapy for ovarian cancer. Curr Opin Obstet
Gynecol. 13:47–51. 2001. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shirakawa T: The current status of
adenovirus-based cancer gene therapy. Mol Cells. 25:462–466.
2008.PubMed/NCBI
|
5
|
Kang E and Yun CO: Current advances in
adenovirus nanocomplexes: more specificity and less immunogenicity.
BMB Rep. 43:781–788. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Pesonen S, Kangasniemi L and Hemminki A:
Oncolytic adenoviruses for the treatment of human cancer: focus on
translational and clinical data. Mol Pharm. 8:12–28. 2011.
View Article : Google Scholar
|
7
|
Panigrahi S, Klonisch T and Los M: The art
of killing: double stroke with apoptin and survivin as a novel
approach in cancer therapy. Cancer Biol Ther. 7:1061–1062. 2008.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Hashimoto Y, Tazawa H, Teraishi F, et al:
The hTERT promoter enhances the antitumor activity of an oncolytic
adenovirus under a hypoxic microenvironment. PLoS One.
7:e392922012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kovalenko OA, Kaplunov J, Herbig U, et al:
Expression of (NES-)hTERT in cancer cells delays cell cycle
progression and increases sensitivity to genotoxic stress. PLoS
One. 5:e108122010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chan G, Kamarudin MN, Wong DZ, et al:
Mitigation of H(2)O(2)-induced mitochondrial-mediated apoptosis in
NG108-15 cells by novel mesuagenin C from Mesua kunstleri (King)
Kosterm. Evid Based Complement Alternat Med. 2012:1565212012.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Byczkowska A, Kunikowska A and Kaźmierczak
A: Determination of ACC-induced cell-programmed death in roots of
Vicia faba ssp minor seedlings by acridine orange and ethidium
bromide staining. Protoplasma. 250:121–128. 2013. View Article : Google Scholar :
|
12
|
Li X1, Liu Y, Wen Z, et al: Potent
anti-tumor effects of a dual specific oncolytic adenovirus
expressing apoptin in vitro and in vivo. Mol Cancer. 9:102010.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang M, Wang J, Li C, et al: Potent
growth-inhibitory effect of a dual cancer-specific oncolytic
adenovirus expressing apoptin on prostate carcinoma. Int J Oncol.
42:1052–1060. 2013.PubMed/NCBI
|
14
|
Los M, Panigrahi S, Rashedi I, et al:
Apoptin, a tumor-selective killer. Biochim Biophys Acta.
1793:1335–1342. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Backendorf C, Visser AE, de Boer AG, et
al: Apoptin: therapeutic potential of an early sensor of
carcinogenic transformation. Annu Rev Pharmacol Toxicol.
48:143–169. 2008. View Article : Google Scholar
|
16
|
Pavet V, Portal MM, Moulin JC, Herbrecht R
and Gronemeyer H: Towards novel paradigms for cancer therapy.
Oncogene. 30:1–20. 2011. View Article : Google Scholar
|
17
|
Ye F, Zhong B, Dan G, et al: Therapeutic
anti-tumor effect of exogenous apoptin driven by human survivin
gene promoter in a lentiviral construct. Arch Med Sci. 9:561–568.
2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
O’Sullivan RJ and Karlseder J: Telomeres:
protecting chromosomes against genome instability. Nat Rev Mol Cell
Biol. 11:171–181. 2010.
|
19
|
Antoniou KM, Margaritopoulos GA, Proklou
A, et al: Investigation of telomerase/telomeres system in bone
marrow mesenchymal stem cells derived from IPF and RA-UIP. J
Inflamm (Lond). 9:272012. View Article : Google Scholar
|
20
|
Vähä-Koskela MJ, Heikkilä JE and Hinkkanen
AE: Oncolytic viruses in cancer therapy. Cancer Lett. 254:178–216.
2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nettelbeck DM: Cellular genetic tools to
control oncolytic adenoviruses for virotherapy of cancer. J Mol Med
(Berl). 86:363–377. 2008. View Article : Google Scholar
|
22
|
Wu Y, Zhang X, Wang X, et al: Apoptin
enhances the oncolytic properties of Newcastle disease virus.
Intervirology. 55:276–286. 2012. View Article : Google Scholar
|
23
|
Jiang J, Cole D, Westwood N, et al:
Crucial roles for protein kinase C isoforms in tumor-specific
killing by apoptin. Cancer Res. 70:7242–7252. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kang X, Chen W, Kim RH, Kang MK and Park
NH: Regulation of the hTERT promoter activity by MSH2, the hnRNPs K
and D, and GRHL2 in human oral squamous cell carcinoma cells.
Oncogene. 28:565–574. 2009. View Article : Google Scholar
|
25
|
Xie X, Hsu JL, Choi MG, et al: A novel
hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol
Cancer Ther. 8:2375–2382. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Tan J, Li W and Wang P: Telomerase reverse
transcriptase promoter-driven expression of iodine pump genes for
targeted radioiodine therapy of malignant glioma cells. Chin J
Cancer. 30:574–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Liu L, Wu W, Zhu G, et al: Therapeutic
efficacy of an hTERT promoter-driven oncolytic adenovirus that
expresses apoptin in gastric carcinoma. Int J Mol Med. 30:747–754.
2012.PubMed/NCBI
|